BR112020010843A2 - oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota - Google Patents

oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota Download PDF

Info

Publication number
BR112020010843A2
BR112020010843A2 BR112020010843-0A BR112020010843A BR112020010843A2 BR 112020010843 A2 BR112020010843 A2 BR 112020010843A2 BR 112020010843 A BR112020010843 A BR 112020010843A BR 112020010843 A2 BR112020010843 A2 BR 112020010843A2
Authority
BR
Brazil
Prior art keywords
human
hmo
akkermansia
abundance
human milk
Prior art date
Application number
BR112020010843-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Louise Kristine Vigsnæs
Bruce McConnell
Original Assignee
Glycom A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom A/S filed Critical Glycom A/S
Publication of BR112020010843A2 publication Critical patent/BR112020010843A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112020010843-0A 2017-11-30 2018-11-30 oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota BR112020010843A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201700680 2017-11-30
DKPA201700680 2017-11-30
DKPA201700690 2017-12-05
DKPA201700690 2017-12-05
PCT/IB2018/059501 WO2019106620A1 (en) 2017-11-30 2018-11-30 Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation

Publications (1)

Publication Number Publication Date
BR112020010843A2 true BR112020010843A2 (pt) 2020-11-10

Family

ID=66664406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020010843-0A BR112020010843A2 (pt) 2017-11-30 2018-11-30 oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota

Country Status (7)

Country Link
US (1) US20200323921A1 (cg-RX-API-DMAC7.html)
EP (1) EP3716983A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021504420A (cg-RX-API-DMAC7.html)
KR (1) KR102741265B1 (cg-RX-API-DMAC7.html)
CN (1) CN111683665A (cg-RX-API-DMAC7.html)
BR (1) BR112020010843A2 (cg-RX-API-DMAC7.html)
WO (1) WO2019106620A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
JP2022513524A (ja) 2018-12-19 2022-02-08 グリコム・アクティーゼルスカブ 低fodmap食を使用してヒトを治療するための組成物および方法
US20220054515A1 (en) * 2018-12-21 2022-02-24 Glycom A/S Composition and method for promoting intestinal barrier healing
EP3980025A4 (en) * 2019-06-05 2023-06-14 Glycom A/S HUMAN MILK OLIGOSACCHARIDES FOR USE IN THE TREATMENT OF SYMPTOMS IN A PATIENT SUFFERING FROM NON-CELIAC GLUTEN AND/OR WHEAT SENSITIVITY
AU2020354581A1 (en) * 2019-09-24 2022-03-03 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
WO2021094993A1 (en) * 2019-11-14 2021-05-20 Glycom A/S Synthetic composition for balancing the bile acid profile in the intestine
US11331329B2 (en) 2020-05-13 2022-05-17 Glycosyn LLC Fucosylated oligosaccharides for prevention of coronavirus infection
EP4149482A4 (en) 2020-05-13 2024-05-22 Glycosyn LLC 2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION
US11896603B2 (en) * 2020-06-12 2024-02-13 The Regents Of The University Of California Oligosaccharide as therapeutic agent for alcohol associated liver disease
JP2023536090A (ja) * 2020-07-31 2023-08-23 アボット・ラボラトリーズ 脂肪肝疾患を予防、低減または遅延させる方法
WO2022117829A1 (en) * 2020-12-04 2022-06-09 Société des Produits Nestlé S.A. Compositions comprising human milk oligosaccharides for use in a subject to support night sleep duration
KR102456307B1 (ko) * 2021-11-10 2022-10-19 충남대학교산학협력단 3’-시알릴락토오스, 6’-시알릴락토오스 또는 이의 염을 유효성분으로 포함하는 감염에 의한 다발성 장기부전의 예방 또는 치료용 조성물
JP2023096870A (ja) * 2021-12-27 2023-07-07 株式会社明治 アッカーマンシア属細菌の増殖促進剤
US20260165955A1 (en) 2022-03-18 2026-06-18 Meiji Co., Ltd. Composition for controlling growth of bacteria of the genus collinsella and use thereof
CN115089596A (zh) * 2022-06-20 2022-09-23 自然资源部第三海洋研究所 新琼寡糖用于制备治疗抑郁症产品的新用途
WO2024126578A1 (en) * 2022-12-13 2024-06-20 Dsm Ip Assets B.V. Synthetic composition comprising a human milk oligosaccharide for microbiota modulation
CN119138609B (zh) * 2024-11-19 2025-02-25 飞鹤(吉林)乳品有限公司 母乳低聚糖改善母婴肠道菌群的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055944A2 (en) * 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
EP2439264B1 (en) * 2010-10-11 2015-06-03 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
MX356184B (es) * 2010-12-31 2018-05-17 Abbott Lab Fórmulación pediátrica sintética que comprende un probiótico.
AU2012215042B2 (en) * 2011-02-10 2016-01-14 Société des Produits Nestlé S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用
NL2007268C2 (en) * 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
US10639319B2 (en) * 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MX2014012362A (es) * 2012-04-13 2015-05-07 Trustees Boston College Composición prebiótica y métodos de uso.
EP2842560A4 (en) * 2012-04-23 2015-12-02 Univ Kyoto COMPOSITION TO PROMOTE THE GROWTH OF BIFIDOBAKTERIA
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
CN107108677B (zh) * 2014-10-24 2020-08-07 格礼卡姆股份公司 Hmo的混合物
US20170258820A1 (en) * 2014-10-29 2017-09-14 Glycom A/S Synthetic composition and method for promoting mucosal healing
US20160287637A1 (en) * 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US10881674B2 (en) * 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
MX378680B (es) * 2015-03-05 2025-03-11 Soc Des Produits Nestle S A Star Composiciones para usar en la prevencion o el tratamiento de infecciones/inflamaciones gastrointestinales en infantes o niños pequeños.
ES2886951T3 (es) * 2015-09-14 2021-12-21 Glycom As Composición para su uso en la modulación de la microbiota
US10537597B2 (en) * 2015-10-05 2020-01-21 Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos Use of Akkermansia muciniphila for treating inflammatory conditions
US10780103B2 (en) * 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
CN108471793A (zh) * 2016-01-26 2018-08-31 雀巢产品技术援助有限公司 用于婴儿或幼儿以预防或治疗变态反应的包含人乳低聚糖的组合物
EP3589139A4 (en) * 2017-03-01 2020-12-23 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
WO2018207110A1 (en) * 2017-05-09 2018-11-15 Glycom A/S Synthetic composition for microbiota modulation
US20180333426A1 (en) * 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
US11541068B2 (en) * 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing autism spectrum disorder symptoms
EP3743078A4 (en) * 2017-12-22 2022-01-19 Glycom A/S COMPOSITION WITH HMOs TO PREVENT OR REDUCE NOCICEPTION

Also Published As

Publication number Publication date
JP2021504420A (ja) 2021-02-15
US20200323921A1 (en) 2020-10-15
WO2019106620A1 (en) 2019-06-06
CN111683665A (zh) 2020-09-18
KR102741265B1 (ko) 2024-12-11
KR20200091438A (ko) 2020-07-30
EP3716983A1 (en) 2020-10-07
EP3716983A4 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
US12063949B2 (en) Mixture of HMOs
US11696921B2 (en) Synthetic composition for microbiota modulation
KR102741265B1 (ko) 미생물총 조절을 위한 인간 밀크 올리고당 및 그의 합성 조성물
US11529365B2 (en) Synthetic composition for microbiota modulation
US11291677B2 (en) Synthetic composition for microbiota modulation
US11278558B2 (en) Synthetic composition for microbiota modulation
EP3377071B1 (en) Human milk oligosaccharides for treating antibiotic associated complications
US11541069B2 (en) One or more HMOs for reducing or preventing fatigue and/or improving focus or concentration
US11541067B2 (en) HMO compositions and methods for reducing detrimental proteolytic metabolites
US20220378809A1 (en) Synthetic composition for balancing the bile acid profile in the intestine
US20200138838A1 (en) Composition comprising hmss/hmos and use thereof
BR112021011071A2 (pt) Composição e método para o tratamento de seres humanos utilizando dietas com baixo teor de fodmap

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]